Repligen (RGEN) Tops Q2 EPS by 20c, Offers Guidance
Tweet
Share
E-mailGet Alerts RGEN Hot Sheet
Price: $167.60 -1.19%
Revenue Growth %: +9.4%
Financial Fact:
Research and development: 1.89M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +9.4%
Financial Fact:
Research and development: 1.89M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Repligen (NASDAQ: RGEN) reported Q2 EPS of $0.91, $0.20 better than the analyst estimate of $0.71. Revenue for the quarter came in at $207.6 million versus the consensus estimate of $189.6 million.
GUIDANCE:
Repligen sees FY2022 EPS of $3.13-$3.20, versus the consensus of $3.09. Repligen sees FY2022 revenue of $790-810 million, versus the consensus of $789 million.
For earnings history and earnings-related data on Repligen (RGEN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Samsara Inc (IOT) Tops Q2 EPS by 4c, Beats on Revenue; Offers Q3 Guidance
- Asana, Inc. (ASAN) Tops Q2 EPS by 1c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
